Skye Bioscience, Inc. (SKYE) financial statements (2022 and earlier)

Company profile

Business Address 11250 EL CAMINO REAL, SUITE 100
SAN DIEGO, CA 92130
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8,98311,0905,1865,1522,4694,225103
Cash and cash equivalents8,98311,0905,1865,1522,4694,225103
Restricted cash and investments5555555
Receivables131815    
Prepaid expense554   190116114
Other current assets57   035
Other undisclosed current assets 321263225   
Total current assets:9,61211,4345,4695,3822,6644,349226
Noncurrent Assets
Operating lease, right-of-use asset147165     
Property, plant and equipment88801617711
Long-term investments and receivables  4    
Due from related parties  4    
Other noncurrent assets88     
Total noncurrent assets:2432532017711
TOTAL ASSETS:9,85511,6875,4885,3992,6724,350227
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,2425824956323648131,134
Accounts payable8983193825003647321,096
Accrued liabilities     8238
Employee-related liabilities344263113132   
Debt1,975  104647152
Derivative instruments and hedges, liabilities602083982773941465
Due to related parties2201510172177
Other liabilities376   259  
Other undisclosed current liabilities25769264136244264427
Total current liabilities:3,9121,5021,5481,3847871,2112,155
Noncurrent Liabilities
Long-term debt and lease obligation791,9211,6691,5361,434790651
Long-term debt, excluding current maturities 1,8201,6691,5361,434790651
Operating lease, liability79101     
Other undisclosed noncurrent liabilities(79)(101)   496515
Total noncurrent liabilities: 1,9211,6691,5361,4341,2851,167
Total liabilities:3,9913,4223,2172,9202,2212,4963,322
Stockholders' equity
Stockholders' equity attributable to parent5,8648,2652,2712,4794511,853(3,094)
Common stock476476396368288250183
Additional paid in capital52,64452,53244,79443,00638,89738,83532,658
Accumulated deficit(47,256)(44,743)(42,919)(40,894)(38,734)(37,232)(35,935)
Total stockholders' equity:5,8648,2652,2712,4794511,853(3,094)
TOTAL LIABILITIES AND EQUITY:9,85511,6875,4885,3992,6724,350227

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Operating expenses(2,462)(1,819)(1,830)(1,737)(1,319)(1,538)(1,221)
Operating loss:(2,462)(1,819)(1,830)(1,737)(1,319)(1,538)(1,221)
Nonoperating income (expense)(51)(6)(193)(423)(183)242(198)
Interest and debt expense (195)118(185)(186)(183)(172)
Other undisclosed income from continuing operations before equity method investments, income taxes    706  
Loss from continuing operations before equity method investments, income taxes:(2,512)(2,020)(1,904)(2,345)(982)(1,479)(1,590)
Other undisclosed income (loss) from continuing operations before income taxes 195(118) (521)183172
Loss from continuing operations before income taxes:(2,512)(1,825)(2,022)(2,345)(1,502)(1,297)(1,419)
Income tax expense(1) (2)   (2)
Net loss:(2,513)(1,825)(2,024)(2,345)(1,502)(1,297)(1,420)
Other undisclosed net income attributable to parent   185   
Net loss available to common stockholders, basic:(2,513)(1,825)(2,024)(2,161)(1,502)(1,297)(1,420)
Other undisclosed net income (loss) available to common stockholders, diluted 120  343(424) 
Net loss available to common stockholders, diluted:(2,513)(1,705)(2,024)(2,161)(1,159)(1,721)(1,420)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(2,513)(1,825)(2,024)(2,345)(1,502)(1,297)(1,420)
Comprehensive loss:(2,513)(1,825)(2,024)(2,345)(1,502)(1,297)(1,420)
Other undisclosed comprehensive income, net of tax, attributable to parent   185   
Comprehensive loss, net of tax, attributable to parent:(2,513)(1,825)(2,024)(2,161)(1,502)(1,297)(1,420)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: